US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
EP1196430B1
(en)
|
1999-06-29 |
2012-02-15 |
MannKind Corporation |
Purification and stabilization of peptide and protein pharmaceutical agents
|
EA008837B1
(ru)
*
|
2000-06-16 |
2007-08-31 |
Эли Лилли Энд Компани |
Аналоги глюкагоноподобного пептида и их применение
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
DE60134251D1
(de)
*
|
2000-09-18 |
2008-07-10 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
DE60224284T2
(de)
*
|
2001-06-28 |
2008-12-18 |
Novo Nordisk A/S |
Stabile formulierung von modifiziertem glp-1
|
CN1363654A
(zh)
|
2001-07-19 |
2002-08-14 |
上海华谊生物技术有限公司 |
生产促胰岛素分泌肽glp-1(7-36)的基因工程菌以及生产glp-1(7-36)的方法
|
IL160493A0
(en)
|
2001-08-23 |
2004-07-25 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
KR20040054729A
(ko)
*
|
2001-10-18 |
2004-06-25 |
브리스톨-마이어스 스큅 컴퍼니 |
인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1790353A1
(en)
*
|
2001-12-29 |
2007-05-30 |
Novo Nordisk A/S |
Combined use of a GLP-1 compound and a modulator of diabetic late complications
|
CN1332711C
(zh)
*
|
2002-02-20 |
2007-08-22 |
埃米球科技有限公司 |
施用glp-1分子的方法
|
ES2425392T3
(es)
|
2002-03-20 |
2013-10-15 |
Mannkind Corporation |
Cartucho para un aparato de inhalación
|
EP1575490A4
(en)
*
|
2002-06-04 |
2007-08-08 |
Lilly Co Eli |
MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US20050059605A1
(en)
*
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
CN1750842A
(zh)
*
|
2003-02-19 |
2006-03-22 |
研究及应用科学协会股份有限公司 |
Glp-1的类似物
|
EP1633384B1
(en)
|
2003-05-15 |
2012-03-14 |
Trustees Of Tufts College |
Stable analogs of glp-1
|
EP1631308B1
(en)
*
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
WO2004105790A1
(en)
*
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
CN102940879B
(zh)
*
|
2003-06-03 |
2017-06-06 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
SI1641823T1
(sl)
|
2003-06-12 |
2011-12-30 |
Lilly Co Eli |
Fuzijski proteini analogni glp-1
|
CN104826116A
(zh)
*
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
CA2551039C
(en)
*
|
2003-12-16 |
2013-01-29 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R |
Analogues of glp-1
|
EP1694278A4
(en)
*
|
2003-12-16 |
2009-08-12 |
Ipsen Pharma |
GLP-1 PHARMACEUTICAL COMPOSITIONS
|
AU2005203925A1
(en)
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Glucagon-Like Peptide-1 analogs with long duration of action
|
CA2897475C
(en)
|
2004-04-30 |
2018-07-10 |
Dow Agrosciences Llc |
Novel herbicide resistance genes
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
CN1950078A
(zh)
|
2004-06-11 |
2007-04-18 |
诺和诺德公司 |
使用glp-1激动剂抵抗药物诱发的肥胖
|
ATE486064T1
(de)
|
2004-08-20 |
2010-11-15 |
Mannkind Corp |
Katalyse der diketopiperazinsynthese
|
PL1791542T3
(pl)
|
2004-08-23 |
2015-11-30 |
Mannkind Corp |
Sole diketopiperazyny do dostarczania leków
|
ES2442223T3
(es)
*
|
2004-08-31 |
2014-02-10 |
Novo Nordisk A/S |
Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
JP2008515856A
(ja)
*
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
CN106137952B
(zh)
|
2004-11-12 |
2020-11-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
JP4785206B2
(ja)
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン(Exendins)及びその使用
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
EP1864661A1
(en)
*
|
2005-03-18 |
2007-12-12 |
Ajinomoto Co., Inc. |
Prophylactic/therapeutic agent for stress-induced bowel disease
|
WO2006124529A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Eli Lilly And Company |
Glp-1 pegylated compounds
|
TWI364292B
(en)
*
|
2005-06-30 |
2012-05-21 |
Ipsen Pharma Sas |
Glp-1 pharmaceutical compositions
|
AU2006290870B2
(en)
|
2005-09-14 |
2013-02-28 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
|
DK2484202T3
(en)
|
2005-10-28 |
2017-09-11 |
Dow Agrosciences Llc |
NEW HERBICID RESISTANCE GENES
|
ES2507098T3
(es)
|
2005-11-07 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US8334257B2
(en)
|
2005-12-20 |
2012-12-18 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
WO2008063203A2
(en)
*
|
2006-01-27 |
2008-05-29 |
Whitehead Institute For Biomedical Research |
Compositions and methods for efficient gene silencing in plants
|
EP2497484A3
(en)
|
2006-02-22 |
2012-11-07 |
MannKind Corporation |
A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
|
EP2574624A1
(en)
*
|
2006-04-20 |
2013-04-03 |
Amgen Inc. |
GLP-1 compounds
|
ES2351527T3
(es)
|
2006-05-30 |
2011-02-07 |
Intarcia Therapeutics, Inc |
Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
|
CN101466398A
(zh)
*
|
2006-06-09 |
2009-06-24 |
诺瓦提斯公司 |
稳定的胰岛素样生长因子多肽
|
CA2655923A1
(en)
*
|
2006-07-06 |
2008-01-10 |
Amylin Pharmaceuticals, Inc. |
Glucagon-like peptides and uses thereof
|
EP2049567A2
(en)
*
|
2006-07-18 |
2009-04-22 |
Centocor, Inc. |
Human glp-1 mimetibodies, compositions, methods and uses
|
NZ574524A
(en)
|
2006-08-09 |
2011-07-29 |
Intarcia Therapeutics Inc |
Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
|
KR100851560B1
(ko)
*
|
2006-12-27 |
2008-08-11 |
고려대학교 산학협력단 |
새로운 글루카곤 유사 펩타이드-1 (glp-1) 작용제 및 그용도
|
EP2124974B1
(en)
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
CN101041693B
(zh)
*
|
2007-02-06 |
2011-08-17 |
珠海联邦制药股份有限公司 |
一种降血糖多肽及其应用
|
US8454971B2
(en)
|
2007-02-15 |
2013-06-04 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
EP2157967B1
(en)
|
2007-04-23 |
2013-01-16 |
Intarcia Therapeutics, Inc |
Suspension formulations of insulinotropic peptides and uses thereof
|
GB2448895A
(en)
*
|
2007-05-01 |
2008-11-05 |
Activotec Spp Ltd |
GLP-1 like compounds and uses thereof
|
US8464239B2
(en)
*
|
2007-06-11 |
2013-06-11 |
Red Hat, Inc. |
Real-time installation and/or configuration assistant
|
WO2009020802A2
(en)
*
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
MX2010004508A
(es)
*
|
2007-10-24 |
2010-07-02 |
Mannkind Corp |
Suministro de agentes activos.
|
CA2703338A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Method of preventing adverse effects by glp-1
|
JP5771005B2
(ja)
|
2007-10-30 |
2015-08-26 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物
|
WO2009058662A2
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
DK2570147T3
(da)
|
2008-06-13 |
2018-01-29 |
Mannkind Corp |
Tørpulverinhalator og system til lægemiddelindgivelse
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
US8546327B2
(en)
|
2008-06-17 |
2013-10-01 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
PL2300035T3
(pl)
|
2008-06-17 |
2016-04-29 |
Univ Indiana Res & Tech Corp |
Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
|
JP5753779B2
(ja)
|
2008-06-17 |
2015-07-22 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
|
KR101628410B1
(ko)
|
2008-06-20 |
2016-06-08 |
맨카인드 코포레이션 |
흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
|
EP3412300A1
(en)
|
2008-06-27 |
2018-12-12 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
TWI532497B
(zh)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
超快起作用胰島素之用途
|
CN101337989B
(zh)
*
|
2008-08-28 |
2012-10-24 |
中国药科大学 |
一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN101367873B
(zh)
*
|
2008-10-08 |
2011-05-04 |
南开大学 |
一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
|
DK2344519T3
(en)
|
2008-11-07 |
2017-01-23 |
Massachusetts Gen Hospital |
C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
|
KR20110110174A
(ko)
|
2008-12-19 |
2011-10-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
CA2754595C
(en)
|
2009-03-11 |
2017-06-27 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
US8734845B2
(en)
|
2009-06-12 |
2014-05-27 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
SG177609A1
(en)
|
2009-07-13 |
2012-02-28 |
Zealand Pharma As |
Acylated glucagon analogues
|
EP2464370B1
(en)
*
|
2009-08-14 |
2017-03-29 |
Phasebio Pharmaceuticals, Inc. |
Modified vasoactive intestinal peptides
|
LT2462246T
(lt)
|
2009-09-28 |
2017-11-27 |
Intarcia Therapeutics, Inc |
Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
|
JPWO2011052523A1
(ja)
*
|
2009-10-30 |
2013-03-21 |
株式会社糖鎖工学研究所 |
抗原性glp−1アナログの糖鎖付加体
|
CA2778698A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
EP2504019A2
(en)
|
2009-11-25 |
2012-10-03 |
ArisGen SA |
Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
RU2012136450A
(ru)
|
2010-01-27 |
2014-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
CA2797095A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
KR20130111923A
(ko)
|
2010-05-13 |
2013-10-11 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
RU2557301C2
(ru)
*
|
2010-05-17 |
2015-07-20 |
Бетта Фармасьютикалз Ко.,Лтд |
Новые аналоги глюкагон-подобного пептида, композиция и способ применения
|
RU2531455C2
(ru)
|
2010-06-21 |
2014-10-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
CA2796894A1
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
RU2013103763A
(ru)
|
2010-07-02 |
2014-08-10 |
Ангиохем Инк. |
Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
|
US9040481B2
(en)
|
2010-11-02 |
2015-05-26 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
MA34885B1
(fr)
|
2010-12-22 |
2014-02-01 |
Indiana Unversity Res And Technology Corp |
Analogues du glucagon presentant una ctivite de recepteur de gip
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
MY180552A
(en)
|
2011-04-01 |
2020-12-02 |
Mannkind Corp |
Blister package for pharmaceutical cartridges
|
CN102180963B
(zh)
*
|
2011-04-22 |
2014-06-25 |
中国药科大学 |
胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN102219850A
(zh)
*
|
2011-05-03 |
2011-10-19 |
上海格尼生物技术有限公司 |
新的长效glp-1化合物
|
CA2873553C
(en)
|
2011-06-06 |
2020-01-28 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
CN103748109A
(zh)
|
2011-06-22 |
2014-04-23 |
印第安纳大学研究及科技有限公司 |
胰高血糖素/glp-1受体共同激动剂
|
LT2723367T
(lt)
|
2011-06-22 |
2017-08-25 |
Indiana University Research And Technology Corporation |
Bendri gliukagono/glp-1 receptoriaus agonistai
|
EP2729157B1
(en)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
|
TWI596110B
(zh)
*
|
2011-09-23 |
2017-08-21 |
諾佛 儂迪克股份有限公司 |
新穎升糖素類似物
|
WO2013063160A1
(en)
|
2011-10-24 |
2013-05-02 |
Mannkind Corporation |
Methods and compositions for treating pain
|
WO2013074910A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
RU2015101697A
(ru)
|
2012-06-21 |
2016-08-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, обладающие активностью рецептора gip
|
CA2878457C
(en)
|
2012-07-12 |
2021-01-19 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
WO2014066856A1
(en)
|
2012-10-26 |
2014-05-01 |
Mannkind Corporation |
Inhalable influenza vaccine compositions and methods
|
CN103087178A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087175A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087179A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087177A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
CN103087176A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
BR112015023168B1
(pt)
|
2013-03-15 |
2021-08-10 |
Mannkind Corporation |
Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
|
WO2014170496A1
(en)
|
2013-04-18 |
2014-10-23 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
CN114848614A
(zh)
|
2013-07-18 |
2022-08-05 |
曼金德公司 |
热稳定性干粉药物组合物和方法
|
CA2920488C
(en)
|
2013-08-05 |
2022-04-26 |
Mannkind Corporation |
Insufflation apparatus and methods
|
CN104262481B
(zh)
*
|
2013-08-09 |
2018-02-09 |
天津药物研究院有限公司 |
一种侧链修饰的长效glp‑1类似物的制备方法及其应用
|
CN103405753B
(zh)
*
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
ES2818824T3
(es)
|
2014-05-08 |
2021-04-14 |
Phasebio Pharmaceuticals Inc |
Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
|
CN106536547A
(zh)
|
2014-06-04 |
2017-03-22 |
诺和诺德股份有限公司 |
用于医疗用途的glp‑1/胰高血糖素受体共激动剂
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
EP3209682B1
(en)
*
|
2014-10-24 |
2020-12-30 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
CA2976038A1
(en)
|
2015-02-09 |
2016-08-18 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating muscle disease and disorders
|
JP6993235B2
(ja)
|
2015-06-03 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
インプラントの設置及び撤去システム
|
AU2016382394B2
(en)
*
|
2015-12-31 |
2019-07-04 |
Hanmi Pharm. Co., Ltd. |
Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
TWI762706B
(zh)
|
2017-08-24 |
2022-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1組成物及其用途
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
SG11202009467YA
(en)
|
2018-04-05 |
2020-10-29 |
Sun Pharmaceutical Ind Ltd |
Novel glp-1 analogues
|
TWI705820B
(zh)
|
2018-06-22 |
2020-10-01 |
美商美國禮來大藥廠 |
Gip/glp1促效劑組合物
|
JP2022504596A
(ja)
|
2018-10-11 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
ヒトアミリンアナログペプチド及び使用方法
|
JP7221385B2
(ja)
*
|
2018-10-30 |
2023-02-13 |
リウ、チアンニン |
Glp-1受容体アゴニスト活性を有するglp-1ポリペプチドおよびその使用
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
CN110845601B
(zh)
*
|
2019-10-12 |
2021-01-19 |
广东药科大学 |
不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
WO2021144476A1
(en)
|
2020-02-18 |
2021-07-22 |
Novo Nordisk A/S |
Pharmaceutical formulations
|